anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
BACKGROUND/AIM: The evolution of sickle cell disease (SCD) is marked by the occurrence of painful episodes linked to the obstruction of microvessels by sickle cells, known as vaso-occlusive crisis (VOC). The aim of this work was to report the practical aspects of the management of acute pain in adults with SCD. Recommendations based on these practices are also provided.
MATERIALS AND METHODS: This prospective, cross-sectional, descriptive, and analytical study was conducted over a four-month period of all sickle cell patients admitted to emergency departments for VOC. The parameters studied were sociodemographic, clinicobiological, therapeutic, and evolutionary.
RESULTS: There were 118 cases of VOC identified, representing a prevalence of 78.14% of sickle cell emergencies. The mean age of the patients was 28.41 years. The SS sickle cell phenotype accounted for 86.61% of the cases. Osteoarticular pain was the reason for admission for 88.39% of the patients; it was located in the lower limbs in 39.08% and in the spine in 27.1%. Pain intensity was moderate in 6.25% of the patients, intense in 31.25%, and unbearable in 55.55%. Multimodal analgesia was the most commonly used treatment method, combining those of levels one and two (74.31%) and levels one and three (8.25%). The mean dose of morphine administered was 17.14 mg when morphine alone was prescribed for titration, 13.57 mg when paracetamol and morphine were combined, and 15.83 mg when nefopam and morphine were combined. Clinical outcome was favorable in 68.87% of the cases.
CONCLUSION: Wide variability was observed in the modalities of analgesic treatment of sickle cell VOC. These variations reflect different views on the appropriateness of opioids. This study highlights the efficacy of multimodal analgesia in the management of acute pain in patients with SCD, particularly in regard to morphine sparing. Context-specific recommendations will be needed to harmonize practices.
Participants received Bemcentinib (BGB324) capsules orally once daily as a loading dose of 400 milligram (mg) on Days 1, 2, and 3. A dose of 200 mg pembrolizumab was given by intravenous infusion over 30 minutes every 3 weeks in all participants. Dosing of both drugs commenced on Day 1. On days when both BGB324 and pembrolizumab were given, pembrolizumab was given first and participants were observed for 1 hour after the end of infusion before BGB324 was administered. From Day 4 onward, participants received a daily maintenance dose of 200 mg along with Pembrolizumab 200 mg intravenous (IV) infusion over 30 minutes every 3 weeks until disease progression, until an unacceptable toxicity occurred that required treatment withdrawal or withdrawal of consent or until 106 weeks had passed.
Target hemoglobin oxygen saturation (SpO2) 80%. No pharmacologic suppression of chemoreflex afferents. Readout: Responses to electrical baroreflex stimulation.
We designed a multi-center phase II trial of gemcitabine for advanced stage marginal zone B-cell lymphoma. Marginal zone lymphoma needs novel agent to improve clinical course by chemotherapy. Recent trials with new agents for indolent lymphoma shows promising results. Gemcitabine is known to have activity to non-Hodgkin's lymphoma and has less adverse effects than other new agents. With this background gemcitabine will be tried as a single agent for advanced marginal zone lymphoma.

Gemcitabine will be administered with 1,250mg/sq.m on days 1 and 8 every 3 weeks. Response will be assessed by IWC criteria.
OCCUPATIONAL CAUTION

There is no specific work exposure limit established for Isoflurane. However, the National Institute for Occupational Safety and Health Administration (NIOSH) recommends that no worker should be exposed at ceiling concentrations greater than 2 ppm of any halogenated anesthetic agent over a sampling period not to exceed one hour.

The predicted effects of acute overexposure by inhalation of Isoflurane include headache, dizziness or (in extreme cases) unconsciousness. There are no documented adverse effects of chronic exposure to halogenated anesthetic vapors ( Waste Anesthetic Gases or WAGs) in the workplace. Although results of some epidemiological studies suggest a link between exposure to halogenated anesthetics and increased health problems (particularly spontaneous abortion), the relationship is not conclusive. Since exposure to WAGs is one possible factor in the findings for these studies, operating room personnel, and pregnant women in particular, should minimize exposure. Precautions include adequate general ventilation in the operating room, the use of a well-designed and well-maintained scavenging system, work practices to minimize leaks and spills while the anesthetic agent is in use, and routine equipment maintenance to minimize leaks (See PRECAUTIONS).
The invention discloses mulberry bark formula granules, and a preparation method and quality control method thereof. The preparation method comprises the following steps: extracting the raw material mulberry bark herbal pieces with water twice, concentrating under reduced pressure, carrying out spray drying, granulating by a dry process, and the like to obtain the mulberry bark formula granules. Every gram of mulberry bark formula granules is equivalent to 9-13 grams of crude drug. The mulberry bark formula granules are subjected to quality identification by thin-layer chromatography. On the basis of the traditional Chinese medicine decoction, the invention combines the modern high-tech extractor, pharmaceutical technology and thin-layer chromatographic scanning technology, refers to the research of mulberry bark chemical composition to perform extraction process research and thin-layer chromatography identification method research on the mulberry bark, thereby obtaining the mulberry bark formula granules which can be taken by being directly dissolved before use. The medicine can implement complete component extraction, scientific production and controllable quality, and can implement large-scale production. The medicine is convenient and sanitary to take, and convenient for storage.
BACKGROUND Over the past decades, total knee arthroplasty (TKA) in China has increased substantially. Owing to a lack of a joint registry, there is restricted information concerning the epidemiology of TKA failures in China. We aimed to (1) investigate the etiology of TKA failures in a cohort of Chinese patients and (2) determine the related demographic and anthropometric risk factors in Jilin, China, to have a look at the actual situation. MATERIAL AND METHODS A total of 1927 primary and 109 revision TKAs performed between April 2014 and May 2022 were analyzed in this retrospective study. Patient demographics and anthropometric measures, the interval from primary TKA to revision procedures, and the mechanisms for primary TKA failure were evaluated. A chi-square test, unpaired t test, and multivariate logistic regression were used to investigate the relationships between different factors and TKA failures. RESULTS The leading failure mechanism was infection (53.3%), followed by aseptic loosening (21.5%), stiffness (15.0%), instability (3.7%), malposition (2.8%), periprosthetic fractures (2.8%), and extensor mechanism disruption (0.9%). Infection (59.7%) was the main reason for early revision. Aseptic loosening (43.3%) was the leading cause of late revision. The male ratio in infection patients was higher (35.1% vs 20.6%). The smoking rate in patients with revision and infection was higher (18.9%, 23.9% vs 7%) than in primary patients. There was no difference in BMI between groups. CONCLUSIONS The leading cause of revision TKA in Jilin, China, was infection, followed by aseptic loosening and stiffness. Sex and smoking history were associated with TKA failures in this region.
The invention relates to applications of Chukrasone A in antidepressant medicines. The invention provides the applications of Chukrasone A in antidepressant medicines. Chukrasone A of the invention can be used as medicines to prevent or cure depression. The applications of Chukrasone A in antidepressant medicines of the invention are discloses for the first time. The molecular skeleton is novel, so that the antidepressant activity is surprisingly strong, and it is impossible to estimate the antidepressant activity according to the antidepressant activities of other compounds. Chukrasone A possesses outstanding substantiality, and the applications of Chukrasone A in antidepressant medicines possess significant advantages.
The invention provides immune-enhanced virus-like particles, an expression vector thereof, and preparation and application thereof. Protein subunit forming the immune-enhanced virus-like particles provided by the invention is a fusion protein of hepatitis B virus core antigen and polypeptide with an amino acid sequence of SEQ ID NO:1. According to the invention, with a genetic engineering recombination technology, an immune-enhanced virus-like particle expression vector is constructed on a basis of human hepatitis B core antigen virus-like particles. With the expression vector, through forming fusion protein or with a chemical coupling method, an antigenic determinant is presented on the surface of the immune-enhanced virus-like particles, such that immunogen is prepared, and immune response can be activated, enhanced, and regulated. Therefore, a breakthrough is provided for auto-antigen immunological tolerance, and the immune system can produce high-affinity high-titer antibody aiming at the auto-antigen under induction. Compared with prior art, with the immune-enhanced virus-like particles provided by the invention, vaccine immunogenicity can be maximized.
Fibroblast growth factor 23 (FGF23) is a novel hormone involved in phosphate and vitamin D physiology. X-linked hypophosphatemia (XLH), autosomal dominant hypophosphatemic rickets (ADHR), and tumor induced osteomalacia (TIO) are 3 rare diseases characterized by rickets/osteomalacia, fractures, and hypophosphatemia secondary to renal phosphate wasting and inappropriately low levels of activated vitamin D (calcitriol), which are caused by excess amounts of or mutated FGF23. FGF23 excess also occurs in renal failure, where elevated FGF23 levels predict increased mortality. Thus, abnormal FGF23 appears to be central to both rare and common diseases. While FGF23 appears to be regulated by vitamin D, dietary and serum phosphate, much is still unknown. The effects of different forms of vitamin D on FGF23 stimulation are not well characterized. Similarly, any racial differences in the regulation of FGF23 by vitamin D have not been investigated.

To address these knowledge deficits, we will randomize 52 vitamin D deficient (25OHD \< or = 24 ng/mL by LC/MS) Caucasian and African-American men and women to treatment with either dietary vitamin D or activated vitamin D for 12 weeks. Our primary endpoint will be the change in FGF23 with dietary versus activated vitamin D.
The stressful experiences, by triggering a cascade of hormonal and neural changes, can produce antinociception commonly referred to as stress-induced antinociception (SIA). Orexin neuropeptides have an essential role in stress responses and pain modulation. The dentate gyrus receives orexinergic projections and has been shown to be involved in pain processing. The current study investigated the possible role of orexin-1 and orexin-2 receptors (OX1r and OX2r, respectively) within the dentate gyrus in SIA in a rat model of formalin-induced pain behavior in one hind paw. Male Wistar rats weighing 230-250 g underwent stereotaxic surgery and a cannula was implanted in their brains, above the dentate gyrus region. Either SB334867 or TCS OX2 29 (OX1r and OX2r antagonists, respectively) was microinjected into the dentate gyrus region at a range of doses at 1, 3, 10, and 30 nmol (control group received DMSO 12% as vehicle), 5 min before the forced swim stress (FSS) exposure. The formalin test was performed to assess pain-related behaviors. The results indicated that FSS exposure relieves pain-related behavior in the early and late phases of the formalin test. Blockade of intra-dentate gyrus OX1 or OX2 receptors reduced the antinociceptive responses induced by FSS in the formalin test, with more impact during the late phase. Our findings support the potential role of intra-dentate gyrus orexin receptors as target sites of orexin neurons in painful and stressful situations. Therefore, understanding the exact mechanisms of SIA and the role of the orexinergic system in this phenomenon can lead to identifying the strategies to guide future research and offer a new approach to discovering new pain therapeutic agents.
Total extra peritoneal repair will be performed in this arm for the patients due to unilateral inguinal hernia. The 15x12 cm mesh will be marked with titanium clips from its 4 corners and placed in the hernia area. The mesh will not be detected in any way.
<P>PROBLEM TO BE SOLVED: To provide a method for producing plate polymer particles having thin and uniform thickness and suitable as particles for the production of cosmetics and industrial particles for the production of coloring materials, water-based inks, etc., a method for producing the plate polymer particles having uniform particle size distribution and arbitrary shape, and a resin layer transfer sheet used for the above production methods.  <P>SOLUTION: The method for the production of plate polymer particles comprises the use of a resin layer transfer sheet at least having a resin layer on a substrate, the thermal transfer of the resin layer to a transfer object, the peeling of the resin layer and the crushing of the peeled layer. The other method for the production of plate polymer particles comprises the thermal transfer of a resin layer in an arbitrary shape by using a thermal head and the peeling of the transferred resin layer. The resin layer transfer sheet has a resin layer composed mainly of a thermoplastic resin on a substrate. An adhesive layer is formed on the resin layer as needed.  <P>COPYRIGHT: (C)2008,JPO&INPIT
The NavSTAR (NS) arm will consist of targeted support delivered by a Patient Navigation team (see Navigation Dyad, below) to enhance participants' linkage with outpatient OUD treatment and recommended medical care for infections and other presenting illnesses. The Navigation Dyad will work in concert with existing resources in the hospital system and broader community to ensure continuity of care (initial linkage and subsequent retention) during the 6-month period after hospital discharge when patients are at elevated risk of disengaging from care, inpatient readmission, and other adverse outcomes.
Subjects prescribed diet alone to treat their PKU who have \>1/3 of monitoring phenylalanine levels (with at least 3 levels measured) outside the target treatment range in the 6 months preceding enrolment. Target therapeutic range is 120 - 360 umol/L for age \<12 years and 120 - 600 umol/L for age ≥ 12 years.
QUESTRAN ® (Cholestyramine for Oral Suspension USP), the chloride salt of a basic anion exchange resin, a cholesterol lowering agent, is intended for oral administration. Cholestyramine resin is quite hydrophilic, but insoluble in water. The cholestyramine resin in QUESTRAN is not absorbed from the digestive tract. Four grams of anhydrous cholestyramine resin is contained in 9 grams of QUESTRAN powder. Four grams of anhydrous cholestyramine resin is contained in 5 grams of QUESTRAN LIGHT. It is represented by the following structural formula:

Cholesterol is probably the sole precursor of bile acids. During normal digestion, bile acids are secreted into the intestines. A major portion of the bile acids is absorbed from the intestinal tract and returned to the liver via the enterohepatic circulation. Only very small amounts of bile acids are found in normal serum.

QUESTRAN resin adsorbs and combines with the bile acids in the intestine to form an insoluble complex which is excreted in the feces. This results in a partial removal of bile acids from the enterohepatic circulation by preventing their absorption.

The increased fecal loss of bile acids due to QUESTRAN administration leads to an increased oxidation of cholesterol to bile acids, a decrease in beta lipoprotein or low density lipoprotein plasma levels and a decrease in serum cholesterol levels. Although in man, QUESTRAN produces an increase in hepatic synthesis of cholesterol, plasma cholesterol levels fall.

In patients with partial biliary obstruction, the reduction of serum bile acid levels by QUESTRAN reduces excess bile acids deposited in the dermal tissue with resultant decrease in pruritus.

QUESTRAN (Cholestyramine for Oral Suspension USP) contains the following inactive ingredients: acacia, citric acid, D&C Yellow No. 10, FD&C Yellow No. 6, flavor (natural and artificial Orange), polysorbate 80, propylene glycol alginate and sucrose. QUESTRAN LIGHT (Cholestyramine for Oral Suspension USP, Light) contains the following inactive ingredients: aspartame, citric acid, colloidal silicon dioxide, D&C Yellow No. 10, FD&C Red No. 40, flavor (natural and artificial Orange), maltodextrin, propylene glycol alginate and xanthan gum.
Water-soluble powder in sachets of 4 grams. Each sachet contains 1 gram of Creatine, 2.5 grams of D-Ribose, 0.33 mg of B1 vitamin and 0.42 mg of B6 vitamin.
OBJECTS: It remains unclear whether the triglyceride-glucose (TyG) index has correlations with gallstones. This study aimed to investigate the association between TyG index and gallstones.
METHODS: Data was obtained from the 2017-2020 National Health and Nutrition Examination Survey (NHANES). Participants who provided complete data about TyG index and gallstones were included in the analysis. Multivariable regression analysis and subgroup analysis were preformed to estimate the relationship between TyG index and gallstones. Restricted cubic splines (RSC) was employed to calculate the cut off value.
RESULTS: The TyG index was independently associated with gallstones and demonstrates a clear positive correlation (OR = 1.10; 95% CI: 1.01-1.21; p = 0.033). The threshold value is 8.98, showing a positive correlation between TyG index and gallstones when the TyG index is less than 8.98 (Log likelihood ratio P < 0.001). Subgroup analysis indicates that the correlation between TyG and gallstones is mainly observed in individuals with obesity, females, younger individuals, and those with normal blood sugar levels, with these subgroups all acting as mediators between TyG and gallstones.
CONCLUSIONS: Higher TyG index was linked to a higher chance of developing gallstones. Managing insulin resistance (IR) could help reduce the risk of gallstones since the TyG index is an indicator of IR.
The patients will be asked to lie supine for 10 minutes and no changes in posture will be allowed for this period. Abdominal paracentesis will be done either by blind technique (in case the ascites is clinically detectable) or ultrasonography-guided (in cases the ascites is not clinically detectable).
FIELD: cosmetics. SUBSTANCE: cream has bioactive additions: composition of vegetable raw made of spirituous-glycerol extracts of oak bark, origanum herb, oat, horse chestnut fruits, knot weed or a mixture of complex CO 2 -extract of pot-marigold and millet, CO 2 -extract of wild rosemary or CO 2 -extract of milfoil, CO 2 -extract of coriander. At combination with emulsifying base and other components cream-deodorizer promotes the strengthening of surface blood capillaries following by change in capillary field intensity. Cream shows expressed deodorizing effect preventing odor sweat appearance for an average 4.5 h that is 90% by score system. Cream does not display irritating and allergenic effects. EFFECT: enhanced quality of cream. 7 tbl
This study is a prospective active surveillance study of group A streptococcal (GAS) diseases across two hospital sites designed to estimate the local incidence of acute rheumatic fever (ARF), rheumatic heart disease (RHD), acute post streptococcal glomerulonephritis (APSGN) and invasive GAS disease. It is part II of a series of 5 studies including DMID protocols 05-0081, 05-0117, 05-0118, and 06-0081. The study is also designed to assess the clinical features of these GAS diseases. The study will also provide detailed information about the molecular epidemiology of GAS from these diseases. The study will establish an active surveillance system for cases of ARF and APSGN and invasive GAS disease at the Colonial War Hospital, in Suva Fiji and at Lautoka Hospital, Lautoka. In addition, the study will establish an active surveillance system for patients presenting with complications of established RHD at the Colonial War Memorial Hospital in Suva Fiji. The primary objectives of the study are to estimate the incidence of: acute rheumatic fever in the Western and Central divisions of Fiji in children 3-17 years of age and adults 18-40 years; RHD in all ages in the Central division of Fiji; APSGN in the Western and Central divisions of Fiji in children 0-17 years of age; and invasive GAS disease in the Western and Central divisions of Fiji in all ages. The secondary objectives of the study are to: describe the clinical features of patients presenting with complications of established RHD in the central division of Fiji; establish an ongoing surveillance system for GAS diseases in the Western and Central divisions; describe the clinical features of patients presenting with ARF, APSGN and invasive GAS disease in Fiji; genotypically characterize GAS isolates from patients with ARF, APSGN and invasive GAS disease in Fiji; and measure anti-J8 antibodies in patients with GAS disease. The primary endpoints of the study are to determine the incidence of: confirmed and probable ARF, both first presentation and recurrent cases; RHD in all ages in the Central division of Fiji; confirmed and probable APSGN; and confirmed and probable invasive GAS disease. The secondary endpoints of the study include: incidence of heart failure, atrial fibrillation, stroke and infective endocarditis in patients with RHD presenting to Colonial War Memorial Hospital; distribution of symptoms and signs of ARF in patients presenting to hospital with ARF; distribution of sites of infection in cases of invasive GAS disease; incidence of necrotizing fasciitis and streptococcal toxic shock syndrome; proportion of GAS isolates from patients with ARF, APSGN and invasive GAS disease that contain the J8 epitope and the overall emm-type distribution of GAS isolates; characterization of GAS isolates (C repeat region sequencing and emm-typing); and measurement of anti-J8 antibodies in patients with GAS disease.
Women in this arm receive education on breast cancer and are offered clinical breast exam free of charge at their local clinic for 6 months following the education session. In addition, women are requested to invite their male partners to attend the breast cancer education session and 7 weekly discussion group sessions (5 men-only and 2 with women). The discussion sessions aim to enable men to change gender attitudes and behaviors that deter women's healthcare utilization.
Initial treatment: anlotinib + benmelstobart + nab-paclitaxel + gemcitabine. Maintenance treatment (after 8 cycles): anlotinib + benmelstobart + gemcitabine.